Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s stock price rose 1.6% on Thursday . The stock traded as high as C$1.98 and last traded at C$1.87. Approximately 29,147 shares changed hands during trading, a decline of 72% from the average daily volume of 102,571 shares. The stock had previously closed at C$1.84.
Medicenna Therapeutics Trading Down 7.5 %
The firm has a market cap of C$132.22 million, a PE ratio of -4.55 and a beta of 1.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.51 and a quick ratio of 4.65. The stock’s fifty day simple moving average is C$1.94 and its 200-day simple moving average is C$2.04.
About Medicenna Therapeutics
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- 5 discounted opportunities for dividend growth investors
- Top 3 ETFs to Hedge Against Inflation in 2025
- What Does a Stock Split Mean?
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
